Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1436256 | 0.75 | — | — | |
| SCHEMBL11116133 | 0.75 | — | — | |
| SCHEMBL8036341 | 0.75 | — | — | |
| SCHEMBL5424032 | 0.75 | — | — | |
| SCHEMBL827528 | 0.75 | — | — | |
| SCHEMBL11258835 | 0.75 | — | — | |
| SCHEMBL1960796 | 0.73 | SRC (0.36) | TSHR | |
| SCHEMBL3011286 | 0.72 | KDM4E (0.41) | ALDH1A1 | |
| SCHEMBL16295809 | 0.72 | — | — | |
| SCHEMBL9065476 | 0.72 | ALOX15 (0.39) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 682 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | THE BROAD INSTITUTE, INC. | 2019-09-19 | — | — | US | claimed |
| CN-110114366-A | Two banks quinolone conjugate and application thereof | 百奥维骨有限责任公司 | 2019-08-09 | — | — | CN | claimed |
| CN-108699044-A | New pyrrolidin derivatives | 豪夫迈·罗氏有限公司 | 2018-10-23 | — | — | CN | claimed |
| US-20180289684-A1 | MAPK INHIBITORS | EverBrilliant Pharma Pty Ltd (AU) | 2018-10-11 | — | — | US | claimed |
| CN-104871289-B | Use of a composition comprising a surfactant and a hydrophobising agent to avoid pattern collapse when processing patterned materials having a line spacing dimension of 50nm or less | 巴斯夫欧洲公司 | 2017-10-10 | — | — | CN | claimed |
| US-20170266173-A1 | MAPK INHIBITORS | EVERBRILLIANT PHARMA PTY LTD. (AU) | 2017-09-21 | — | — | US | claimed |
| WO-2017027768-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | THE BROAD INSTITUTE, INC. (US) | 2017-02-16 | — | — | WO | claimed |
| CN-105520941-A | Substituted gamma lactams as therapeutic agents | ALLERGAN INC | 2016-04-27 | — | — | CN | claimed |
| CN-104871289-A | Use of a composition comprising a surfactant and a hydrophobising agent to avoid resistance to pattern collapse when treating patterned materials having a line spacing dimension of 50nm or less | BASF SE | 2015-08-26 | — | — | CN | claimed |
| EP-2758383-A1 | AROMATIC AMIDOTHIAZOLES, COSMETIC OR DERMATOLOGICAL PREPARATIONS CONTAINING SAID AROMATIC AMIDOTHIAZOLES, AND USE THEREOF TO COMBAT OR PREVENT UNDESIRED PIGMENTATION OF THE SKIN | Beiersdorf AG (DE) | 2014-07-30 | — | — | EP | claimed |
| US-20030105164-A1 | Solid phase synthesis of arylretinamides | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-05 | — | — | US | claimed |
| WO-2003003987-A2 | SOLID PHASE SYNTHESIS OF ARYLRETINAMIDES | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-01-16 | — | — | WO | claimed |
| EP-0466319-B1 | Hydroxyalkylation of phenols or thiophenols with cyclic organic carbonates using triorganophosphine catalysts | INDSPEC CHEMICAL CORP (US) | 1998-05-06 | — | — | EP | claimed |
| US-5059723-A | Efficiency; purity | INDSPEC CHEMICAL CORPORATION (US) | 1991-10-22 | — | — | US | claimed |
| US-4932473-A | ENHANCED OIL RECOVERY | SHELL OIL COMPANY (US) | 1990-06-12 | — | — | US | claimed |
| US-4833240-A | SKIN DISORDERS; ANTIINFLAMMATORY AGENTS; ANTIALLLERGENS; ANTITUMOR AGENTS; OPHTHALMOLOGY | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) (FR) | 1989-05-23 | — | — | US | claimed |
| EP-0237075-A2 | Prespotter laundry detergent | S.C. JOHNSON & SON, INC. (US) | 1987-09-16 | — | — | EP | claimed |
| US-4520095-A | STABLE CYAN DYE FOR COLOR DIFFUSION TRANSFER IN SILVER HALIDE EMULSION-CONTAINING FILMS | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1985-05-28 | — | — | US | claimed |
| US-4122256-A | OPTICAL BRIGHTENERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-24 | — | — | US | claimed |
| US-4052433-A | INTERMEDIATES FOR BENZOFURANS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-10-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | C5, IFNG, TERT | ALDH1A1 1848/4885TSHR 3335/4885 |
| US-20170266173-A1 | MAPK INHIBITORS | MAPK1, MAPK4, MAPK3 | ALDH1A1 1797/4885TSHR 2701/4885 |
| US-20030105164-A1 | Solid phase synthesis of arylretinamides | RARA, LRAT, NR2E3 | ALDH1A1 1637/4885TSHR 28/4885 |
| US-20180289684-A1 | MAPK INHIBITORS | MAPK1, MAPK4, MAPK3 | ALDH1A1 1797/4885TSHR 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.